Anaplastic Astrocytoma Drug Market
Global Anaplastic Astrocytoma Drug Market Size, Share & Trends Analysis Report By Type (A-10 and AS-21, AdRTSIL-12, ADU-623, and Others), and By End-User (Hospitals and Clinics, Retail Pharmacy, and Online Pharmacy) Forecast Period (2022-2028) Update Available - Forecast 2024-2030
The global anaplastic astrocytoma drug market is anticipated to grow at a significant CAGR of 4.1% during the forecast period. One of the major factors that are augmenting the growth of the anaplastic astrocytoma drug is the rising prevalence of primary malignant and non-malignant brain tumors. For instance, according to the information provided by the National Brain Tumor Society which highlights the fact that an estimated 700,000 people in the US are living with a primary brain tumor, and approximately 88,970 more will be diagnosed in 2022 and an estimated 72,360 adults age from 40+ will be diagnosed with a primary brain tumor. Adults with anaplastic astrocytomas have the most frequent type of brain tumor, accounting for around 20% of all primary central nervous system tumors. They can be dangerous if not addressed promptly. Anaplastic astrocytoma is a rare kind of brain or spine cancer that begins in the brain or spine. Anaplastic astrocytoma is malignant astrocytoma caused by mutations in the DNA of astrocytes. Moreover, the rising number of drug candidates in the pipeline is also acting as an important factor providing the opportunity for market growth.
Impact of COVID-19 Pandemic on Global Anaplastic Astrocytoma Drug Market
The COVID-19 pandemic had impacted the global anaplastic astrocytoma drug market significantly owning to the lockdown in most nations to control the spread of the virus. The commencement of the COVID-19 pandemic, and the global lockdown, had an impact on global industry growth. Elective surgeries were cancelled to avoid viral spread, and only needed surgical procedures were allowed to be performed. The emergency procedures followed the safety guidelines when treating the patient in order to keep the virus transmission to a minimum. As a result, this scenario had an impact on the anaplastic astrocytoma therapy market. However, after the lifting of regulatory measures and the continuing of surgical treatment operations, the market is expected to rise and recover in the future.
Segmental Outlook
The global anaplastic astrocytoma drug market is segmented based on type and end-user. Based on the type, the market is sub-segmented into A-10 and AS-21, AdRTSIL-12, ADU-623, and others (Temozolomide). Based on the end-user, the market is sub-segmented into hospitals and clinics, retail pharmacy, and online pharmacy. Based on end-user, the hospitals and clinics segment is expected to hold a significant share in the market due to growing sales of prescription-based pharmaceuticals and rising patient visits for treatment of oncology disorders, particularly brain cancer.
Global Anaplastic Astrocytoma Drug Market Share by Type, 2021 (%)
The AdRTSIL-12 Segment Holds the Prominent Share in the Global Anaplastic Astrocytoma Drug Market
The AdRTSIL-12 segment holds the prominent market share and is anticipated to grow significantly during the forecast period in the global anaplastic astrocytoma drug market in the type segment. AdRTSIL-12 is a type of CAR T cell therapy. AdRTSIL-12 is a chimeric antigen receptor (CAR) immunotherapy (CARs). It offers the potential to treat cancer and other diseases by reprogramming a patient's immune cells to fight the disease, such as some forms of malignancies or tumors in blood disorders such as acute lymphoblastic leukemia (ALL) and lymphoma.
Regional Outlooks
The global Anaplastic astrocytoma drug market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). Among the regions, the Asia Pacific anticipated to hold significant share in the market followed by North America, and then Europe.
Global Anaplastic Astrocytoma Drug Market Growth, by Region 2022-2028
The Asia-Pacific Region Expected to Hold Considerable Share in the Global Anaplastic Astrocytoma Drug Market
The Asia-Pacific region holds a significant share and is anticipated to grow fastest during the forecast period in the anaplastic astrocytoma drug market. The presence of emerging countries such as China, Japan, India, and South Korea are taking big initiatives to fuel up the overall anaplastic astrocytoma market. Additionally, the involvement in the region for anaplastic astrocytoma-related drug trials is also supporting the growth of the market.
Market Players Outlook
The major companies serving the global anaplastic astrocytoma drug market include Avid Bioservices, Inc., Merck & Co., Mylan N.V., Teva Pharmaceuticals Industries Ltd., Novartis AG, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in November 2021, Penn Medicine entered a new phase in cell therapy for glioblastoma brain cancer. Researchers are on the verge of developing the next generation of chimeric antigen receptor cellular treatments (CARs), which could provide patients with GBM and other solid tumors new hope.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global anaplastic astrocytoma drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Anaplastic Astrocytoma Drug Market
• Recovery Scenario of Global Anaplastic Astrocytoma Drug Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Avid Bioservices, Inc.
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. Merck & Co., Inc.
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. Mylan N.V.
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.1.4. Novartis AG
3.1.4.1. Overview
3.1.4.2. Financial Analysis
3.1.4.3. SWOT Analysis
3.1.4.4. Recent Developments
3.1.5. Teva Pharmaceutical Industries Ltd.
3.1.5.1. Overview
3.1.5.2. Financial Analysis
3.1.5.3. SWOT Analysis
3.1.5.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players
4. Market Segmentation
4.1. Global Anaplastic Astrocytoma Drug Market by Type
4.1.1. A-10 and AS-21
4.1.2. AdRTSIL-12
4.1.3. ADU-623
4.1.4. Others (Temozolomide)
4.2. Global Anaplastic Astrocytoma Drug Market by End-User
4.2.1. Hospitals and clinics
4.2.2. Retail Pharmacy
4.2.3. Online Pharmacy
5. Regional Analysis
5.1. North America
5.1.1. US
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Actiza Pharmaceutical Pvt. Ltd.
6.2. Amgen Inc.
6.3. Boehringer Ingelheim International GmbH
6.4. Celldex Therapeutics
6.5. CELON LABS
6.6. Cipla Inc.
6.7. F. Hoffmann-La Roche Ltd.
6.8. Genentech, Inc.
6.9. GLS Pharma Pvt. Ltd.
6.10. Isarna Therapeutics
6.11. Moleculin Biotech, Inc.
6.12. Oncotelic Inc.
6.13. Penn Medicine
6.14. Perrigo Co. plc.
6.15. Pfizer Inc.
6.16. PHARMA’S ALMANAC
6.17. Wellona Pharma
1. GLOBAL ANAPLASTIC ASTROCYTOMA DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL A-10 and AS-21 ANAPLASTIC ASTROCYTOMA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL AdRTSIL-12 ANAPLASTIC ASTROCYTOMA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL ADU-623 ANAPLASTIC ASTROCYTOMA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL OTHERS (TEMOZOLOMIDE) ANAPLASTIC ASTROCYTOMA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL ANAPLASTIC ASTROCYTOMA DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
7. GLOBAL HOSPITALS AND CLINICS ANAPLASTIC ASTROCYTOMA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL RETAIL PHARMACY ANAPLASTIC ASTROCYTOMA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL ONLINE PHARMACY ANAPLASTIC ASTROCYTOMA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL ANAPLASTIC ASTROCYTOMA DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
11. NORTH AMERICAN ANAPLASTIC ASTROCYTOMA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
12. NORTH AMERICAN ANAPLASTIC ASTROCYTOMA DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
13. NORTH AMERICAN ANAPLASTIC ASTROCYTOMA DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
14. EUROPEAN ANAPLASTIC ASTROCYTOMA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
15. EUROPEAN ANAPLASTIC ASTROCYTOMA DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
16. EUROPEAN ANAPLASTIC ASTROCYTOMA DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
17. ASIA-PACIFIC ANAPLASTIC ASTROCYTOMA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC ANAPLASTIC ASTROCYTOMA DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC ANAPLASTIC ASTROCYTOMA DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
20. REST OF THE WORLD ANAPLASTIC ASTROCYTOMA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
21. REST OF THE WORLD ANAPLASTIC ASTROCYTOMA DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
22. REST OF THE WORLD ANAPLASTIC ASTROCYTOMA DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL ANAPLASTIC ASTROCYTOMA DRUG MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL ANAPLASTIC ASTROCYTOMA DRUG MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL ANAPLASTIC ASTROCYTOMA DRUG MARKET, 2022-2028 (%)
4. GLOBAL ANAPLASTIC ASTROCYTOMA DRUG MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL A-10 AND AS-21 ANAPLASTIC ASTROCYTOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL AdRTSIL-12 ANAPLASTIC ASTROCYTOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL ADU-623 ANAPLASTIC ASTROCYTOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL OTHERS (TEMOZOLOMIDE) ANAPLASTIC ASTROCYTOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL ANAPLASTIC ASTROCYTOMA DRUG MARKET SHARE BY END-USER, 2021 VS 2028 (%)
10. GLOBAL HOSPITALS AND CLINICS ANAPLASTIC ASTROCYTOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL RETAIL PHARMACY ANAPLASTIC ASTROCYTOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL ONLINE PHARMACY ANAPLASTIC ASTROCYTOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL ANAPLASTIC ASTROCYTOMA DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. US ANAPLASTIC ASTROCYTOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
15. CANADA ANAPLASTIC ASTROCYTOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
16. UK ANAPLASTIC ASTROCYTOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
17. FRANCE ANAPLASTIC ASTROCYTOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
18. GERMANY ANAPLASTIC ASTROCYTOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
19. ITALY ANAPLASTIC ASTROCYTOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
20. SPAIN ANAPLASTIC ASTROCYTOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
21. REST OF EUROPE ANAPLASTIC ASTROCYTOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
22. INDIA ANAPLASTIC ASTROCYTOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
23. CHINA ANAPLASTIC ASTROCYTOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
24. JAPAN ANAPLASTIC ASTROCYTOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
25. SOUTH KOREA ANAPLASTIC ASTROCYTOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
26. REST OF ASIA-PACIFIC ANAPLASTIC ASTROCYTOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF THE WORLD ANAPLASTIC ASTROCYTOMA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
